NAFDAC APPROVES FLOXIUM!  (JULY, 2007)

The drug regulatory authority in Nigeria, NAFDAC (National Agency for Food and Drug Administration and Control) has approved the sales, distribution and use of Floxium in Nigeria.

Floxium contains levofloxacin, a broad spectrum, third generation fluoroquinolone that is effective in the treatment of infections caused by gram +ve, gram –ve, aerobic and anaerobic bacteria. It is also effective in the treatment of infections caused by intracellular pathogens. It has been found useful as an adjunct therapy in the management of tuberculosis. 

This third generation fluoroquinolone will offer significant value to doctors and patients alike in management of bacteria infections.

Pharmacist Ibukun Oyelohunnu, the Chief Executive Officer of Solidum Pharmaceuticals mentioned that this is an exciting time for the Nigeria healthcare physicians as Solidum Pharmaceuticals will ensure that Floxium is made available to the patients at a highly affordable price to enable many patients benefit from the unique advantages of Floxium as compared to other antibiotics.

Floxium is indicated for the treatment of acute maxillary sinusitis, acute bacterial exacerbation of chronic bronchitis, community-acquired pneumonia, nosocomial pneumonia, complicated skin and skin structure infections, uncomplicated skin and skin structure infections, complicated urinary tract infections, acute pyelonephritis, uncomplicated urinary tract infections, chronic bacteria prostatitis, intra abdominal infections, gynecological Infections, bone infections (acute & chronic), enteric Infections and surgical prophylaxis.